索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王茜.硫化氢在心肌缺血再灌注损伤中的作用机制[J].国际心血管病杂志,2021,04:200-202.
点击复制

硫化氢在心肌缺血再灌注损伤中的作用机制(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年04期
页码:
200-202
栏目:
综述
出版日期:
2021-08-15

文章信息/Info

Title:
-
作者:
王茜
200040 上海市药品和医疗器械不良反应监测中心
Author(s):
-
关键词:
硫化氢;  心肌缺血再灌注损伤;  炎性反应;  细胞凋亡
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.04.003
文献标识码:
-
摘要:
硫化氢(H2S)是一种气体信号分子,在哺乳动物体内广泛存在。内源性H2S主要在线粒体中代谢。外源性或内源性H2S对心肌缺血再灌注损伤均具有保护作用,主要作用机制包括抗炎、抗氧化、抗凋亡和促进血管新生等。该文介绍H2S在心肌缺血再灌注损伤中的作用和机制及H2S供体相关药物,以期对缺血性心脏病的干预提供新思路。
Abstract:
-

参考文献/References

[1] Martelli A, Testai L, Breschi MC, et al. Hydrogen sulphide: novel opportunity for drug discovery[J]. Med Res Rev, 2012, 32(6):1093-1130.
[2] Li H, Zhang C, Sun W, et al. Exogenous hydrogen sulfide restores cardioprotection of ischemic post-conditioning via inhibition of mPTP opening in the aging cardiomyocytes[J]. Cell Biosci, 2015, 5:43.
[3] Li H, Wang Y, Wei C, et al. Mediation of exogenous hydrogen sulfide in recovery of ischemic post-conditioning-induced cardioprotection via down-regulating oxidative stress and up-regulating PI3K/Akt/GSK-3β pathway in isolated aging rat hearts[J]. Cell Biosci, 2015, 5:11.
[4] Wu D, Si W, Wang M, et al. Hydrogen sulfide in cancer: friend or foe?[J]. Nitric Oxide, 2015, 50:38-45.
[5] Chen Y, Zhang F, Yin J, et al. Protective mechanisms of hydrogen sulfide in myocardial ischemia[J]. J Cell Physiol, 2020, 235(12):9059-9070.
[6] Bliksoen M, Kaljusto ML, Vaage J, et al. Effects of hydrogen sulphide on ischaemia-reperfusion injury and ischaemic preconditioning in the isolated, perfused rat heart[J]. Eur J Cardiothorac Surg, 2008, 34(2):344-349.
[7] King AL, Polhemus DJ, Bhushan S, et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent[J]. Proc Natl Acad Sci USA, 2014, 111(8):3182-3187.
[8] Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling[J]. Nat Rev Cardiol, 2014, 11(5):255-265.
[9] Gemici B, Wallace JL. Anti-inflammatory and cytoprotective properties of hydrogen sulfide[J]. Methods Enzymol, 2015, 555:169-193.
[10] Sodha NR, Clements RT, Feng J, et al. Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury[J]. J Thorac Cardiovasc Surg, 2009, 138(4):977-984.
[11] Marino A, Martelli A, Citi V, et al. The novel H2S donor 4-carboxy-phenyl isothiocyanate inhibits mast cell degranulation and renin release by decreasing intracellular calcium[J]. Br J Pharmacol, 2016, 173(22):3222-3234.
[12] Roviezzo F, Bertolino A, Sorrentino R, et al. Hydrogen sulfide inhalation ameliorates allergen induced airway hypereactivity by modulating mast cell activation[J]. Pharmacol Res, 2015, 100:85-92.
[13] Vasquez-trincado C, Garcia-carvajal I, Pennanen C, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease[J]. J Physiol, 2016, 594(3):509-525.
[14] Zhang Z, Jin S, Teng X, et al. Hydrogen sulfide attenuates cardiac injury in takotsubo cardiomyopathy by alleviating oxidative stress[J]. Nitric Oxide, 2017, 67:10-25.
[15] Calvert JW, Elston M, Nicholson CK, et al. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice[J]. Circulation, 2010, 122(1):11-19.
[16] Ling K, Xu A, Chen Y, et al. Protective effect of a hydrogen sulfide donor on balloon injury-induced restenosis via the Nrf2/HIF-1α signaling pathway[J]. Int J Mol Med, 2019, 43(3):1299-1310.
[17] Ruiz-meana M, Nunez E, Miro-casas E, et al. Ischemic preconditioning protects cardiomyocyte mitochondria through mechanisms independent of cytosol[J]. J Mol Cell Cardiol, 2014, 68:79-88.
[18] Yao X, Tan G, He C, et al. Hydrogen sulfide protects cardiomyocytes from myocardial ischemia-reperfusion injury by enhancing phosphorylation of apoptosis repressor with caspase recruitment domain[J]. Tohoku J Exp Med, 2012, 226(4):275-285.
[19] Citi V, Piragine E, Testai L, et al. The role of hydrogen sulfide and H2S-donors in myocardial protection against ischemia/reperfusion injury[J]. Curr Med Chem, 2018, 25(34):4380-4401.
[20] Szabo C, Papapetropoulos A. Hydrogen sulphide and angiogenesis: mechanisms and applications[J]. Br J Pharmacol, 2011, 164(3):853-865.
[21] Polhemus D, Kondo K, Bhushan S, et al. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis[J]. Circ Heart Fail, 2013, 6(5):1077-1086.
[22] Wen YD, Wang H, Zhu YZ. The drug developments of hydrogen sulfide on cardiovascular disease[J]. Oxid Med Cell Longev, 2018, 2018:4010395.
[23] Qabazard B, Masocha W, Khajah M, et al. H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice[J]. Biomed Pharmacother, 2020, 127:110210.
[24] Feng S, Zhao Y, Xian M, et al. Biological thiols-triggered hydrogen sulfide releasing microfibers for tissue engineering applications[J]. Acta Biomater, 2015, 27:205-213.
[25] Zhao Y, Yang C, Organ C, et al. Design, synthesis, and cardioprotective effects of N-mercapto-based hydrogen sulfide donors[J]. J Med Chem, 2015, 58(18):7501-7511.
[26] Li Z, Organ CL, Zheng Y, et al. Novel esterase-activated hydrogen sulfide donors attenuate?myocardial ischemia/reperfusion injury[J].Circulation, 2016, 134(Suppl 1):A17903.

备注/Memo

备注/Memo:
通信作者:王茜,E-mail:wangqianlily@126.com
更新日期/Last Update: 2021-08-15